Stay informed about what's going on in the industry.
- Envarsus® XR Demonstrates Lower Treatment Failure Rate in African–Americans Compared to Twice–Daily Tacrolimus (Prograf®) - 6/30/2014
- Research Collaboration between American Diabetes Association and Boehringer Ingelheim to Focus on Chronic Kidney Disease and Renal Insufficiency - 6/2/14
- GSK receives US approval for once-weekly type 2 diabetes treatment, Tanzeum™ (albiglutide) - 4/15/14
- Affymax, Inc. and Takeda Pharmaceuticals America, Inc., Announce FDA Approval of OMONTYS® (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA) for once monthly administration — 4/16/12